Achaogen (a-KAY-o-jen) develops small molecule therapeutics to treat multi-drug resistant bacterial infections, a serious unmet medical need causing hundreds of thousands of deaths worldwide each year.
Achaogen is developing next-generation aminoglycosides. Our lead compounds display broad-spectrum activity against many resistant bacteria that cause systemic infections, including K. pneumoniae, E. coli and MRSA.
Our world-class team has led or participated in the development of several approved and/or late-stage antibacterial compounds, and our scientific advisors include U.S. and European thought leaders in antimicrobial resistance and drug development. We focus these resources on the tasks of compound discovery, lead optimization, and early-stage clinical trials, while leveraging external resources worldwide for screening and hit generation and for later-stage clinical work. This maximizes our capital efficiency, minimizing infrastructure costs while mitigating the risks and costs of late phase trials.
Our state-of-the-art research facility is located on the shores of the San Francisco Bay, five minutes from the San Francisco International Airport, and only fifteen minutes from downtown San Francisco.